文献速递消化道肿瘤放疗姑息放疗与转移瘤

同步放化疗对老年食管鳞状细胞癌寡转移患者的生存影响

Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses.
PubMed 文献 · Radiother Oncol · 2021-10-07

该研究纳入两个中心的314例老年同步寡转移食管鳞状细胞癌患者,比较同步放化疗与单纯化疗的疗效。同步放化疗在客观缓解率、中位无进展生存期和中位总生存期上均优于单纯化疗,且毒性可接受,并支持将≤3个转移灶且累及1个器官作为食管癌寡转移的定义。

要点

  • 同步放化疗较单纯化疗提高客观缓解率59.6% vs 39.9%(P<0.001)。
  • 同步放化疗中位无进展生存期10.0 vs 7.2个月,中位总生存期18.5 vs 15.6个月(P<0.001)。
  • 3级及以上主要毒性为白细胞减少23.2%、放射性食管炎7.3%、放射性肺炎8.6%。

核心结论

  • 同步放化疗在老年同步寡转移食管鳞状细胞癌一线治疗中疗效优于单纯化疗且毒性可接受。
  • 研究支持以≤3个转移灶且累及1个器官作为食管癌寡转移的定义。
  • 基于转移灶数目和肿瘤反应的列线图可有效预测个体化生存。

研究设计与样本

  • 回顾性队列研究,纳入两个中心314例初诊老年同步寡转移食管鳞状细胞癌患者。
  • 151例接受同步放化疗,163例接受单纯化疗。
  • 采用倾向性评分匹配和里程碑分析控制混杂因素,并基于Cox回归模型建立列线图。

主要发现

  • 中位随访42.3个月,同步放化疗组客观缓解率59.6% vs 39.9%(P<0.001)。
  • 同步放化疗组中位无进展生存期10.0 vs 7.2个月(P<0.001),中位总生存期18.5 vs 15.6个月(P<0.001)。
  • 倾向性评分匹配和里程碑分析重复显示相同趋势(P<0.01)。
  • 1-3个转移灶累及1个器官者中位无进展生存期9.0 vs 7.8个月(P=0.008)、中位总生存期17.8 vs 15.2个月(P<0.001),优于4-5个转移灶累及2-3个器官者。
  • Cox多因素分析显示转移灶数目(P=0.012)和肿瘤反应(P<0.001)是与总生存相关的独立预后因素。

关键数值与推荐

  • 同步放化疗组3级及以上白细胞减少发生率为23.2%。
  • 同步放化疗组3级及以上放射性食管炎发生率为7.3%。
  • 同步放化疗组3级及以上放射性肺炎发生率为8.6%。
  • 列线图内部交叉验证一致性指数为0.743。

临床怎么用

  • 老年同步寡转移食管鳞状细胞癌患者可考虑一线同步放化疗而非单纯化疗。
  • 同步放化疗需关注3级及以上白细胞减少、放射性食管炎和放射性肺炎。
  • 列线图可辅助个体化生存预测,纳入转移灶数目和肿瘤反应两个因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the potential benefits of concurrent chemoradiotherapy (CCRT), and to establish a nomogram for predicting survival outcomes of elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma (SOEC). MATERIALS AND METHODS: This study eventually enrolled 314 elderly patients who initially diagnosed with SOEC from two centers. Treatment responses and outcomes of 151 patients receiving CCRT and 163 patients undergoing chemotherapy alone (CT) were compared. Propensity score matching and landmark analyses were performed to control potential confounding factors. A nomogram was established on the basis of the Cox regression model. RESULTS: After a median follow-up of 42.3 months, CCRT was superior to CT alone in objective response rate (ORR, 59.6% vs. 39.9%, P < 0.001), median progression-free survival (PFS, 10.0 vs. 7.2 months, P < 0.001), and median overall survival (OS, 18.5 vs. 15.6 months, P < 0.001). The propensity score matching (PSM) and landmark analyses redemonstrated the same trend (P < 0.01). On hierarchical analysis, patients with 1-3 metastatic lesions involving one organ displayed longer median PFS (9.0 vs. 7.8 months, P = 0.008) and OS (17.8 vs. 15.2 months, P < 0.001) than those with 4-5 metastatic lesions involving 2-3 organs. The major toxicities of grade III or higher for CCRT included leukocytopenia (23.2%), radiation esophagitis (7.3%), and radiation pneumonitis (8.6%). Cox multivariate analysis showed that the number of metastatic lesions (P = 0.012) and tumor response (P < 0.001) were independent prognostic factors associated with OS. A nomogram was established by incorporating the number of metastatic lesions and tumor response, with a concordance index of 0.743 after internal cross-validation. Calibration curves and decision curve analysis confirmed that nomogram had a favorable predictive value for individualized survival. CONCLUSIONS: Compared with CT alone, CCRT exhibited superior efficacy and acceptable toxicity in the first-line treatment for elderly patients with SOEC. The current study supports the oligometastatic definition of ≤3 metastatic lesions involving one organ for esophageal cancer patients. The constructed nomogram can effectively predict the individualized survival.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Shi Z, Zhu X, Ke S, et al. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses. Radiother Oncol. 2021. PMID: 34627936. doi:10.1016/j.radonc.2021.09.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。